Bullboard - Stock Discussion Forum VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and... see more

Add To Watchlist

TSXV:VPT - Post Discussion

VentriPoint Diagnostics Ltd > 👀The @Chinese Society of Echocardiography in the future!🤔

View:

Post by jopatclo on Nov 24, 2024 8:11am

👀The @Chinese Society of Echocardiography in the future!🤔

Now V4.0 Europe & Canada OK CardioLogic Ltd Introducing Ventripoint 4.0!
Interesting See On Linkedin post Victoria Delgado Head of the department of Cardiovascular Imaging 15 h •

& remember https://www.marketsmart.ca/news/ventripoint-advances-sales-marketing-and-distribution-partnership-in-the-largest-market-in-world-for-heart-disease-china/

Dario Freitas aime ceci

I am very grateful to the @Chinese Society of Echocardiography for the kind invitation to participate at the Scientific Sessions. Even if it was online, the photos shared by Prof. Yin transmit the welcoming character and kindness of our Chinese colleagues. Looking forward for more collaborations between @EACVI and the @Chinese Society of Echocardiography in the future! ESC Social Media Team European Society of Cardiology Hospital Universitari Germans Trias i Pujol Germans Trias i Pujol Research Institute (IGTP) Sarah Moharem Elgamal Giovanni Di Salvo Veronique Brassart, PMP Audrey ESPEROU SURREL

& remember https://www.marketsmart.ca/news/ventripoint-advances-sales-marketing-and-distribution-partnership-in-the-largest-market-in-world-for-heart-disease-china/
Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”), (TSXV:VPT; OTC:VPTDF) is pleased to provide a corporate update on sales and marketing activities in China by our joint-venture partner Yutian Medical Shanghai Inc. (“Yutian”).

Yutian has informed the Company that it has achieved a number of milestones in its path from development to commercialization. Some of these developments are noted herein. Yutian has developed a series of products based upon Ventripoint’s knowledge-based reconstruction technology under the name QAS™ to specifically meet the demands of the Chinese market using components sourced in China. They have built and obtained a license for a manufacturing facility in Ma-anshan. The QAS (right ventricle only) has received Chinese FDA (“CFDA”) approval and the QAS analysis procedure has been added to the provincial medical billing catalog in Anhui Province (a province of 62 million people).)